Business & Finance
BioInvent International announces manufacturing agreement with undisclosed US cell therapy company
20 November 2018 -

BioInvent International AB (STO:BINV) announced on Tuesday the signing of a manufacturing agreement with an undisclosed US cell therapy company for the production of cGMP compliant material to support their clinical development programmes.

This manufacturing agreement is expected to generate revenues of approximately USD1.5m, mainly in 2019.

BioInvent International is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer.